Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical diagnostic accuracy and lymph node metastasis patterns in clinical T1bN0M0 esophageal squamous cell carcinoma: a supplementary analysis of JCOG1409.

Esophagus : official journal of the Japan Esophageal Society·2026
Same author

Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A).

Esophagus : official journal of the Japan Esophageal Society·2026
Same author

Prognostic Impact of Postoperative Complications After Neoadjuvant Therapy Followed by Esophagectomy for Esophageal Cancer: An Exploratory Analysis of Phase III Trial JCOG1109.

Annals of surgery·2026
Same author

Thoracic and cardiovascular surgeries in Japan during 2024 : Annual report by the Japanese Association for Thoracic Surgery.

General thoracic and cardiovascular surgery·2026
Same author

Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.

Annals of surgical oncology·2026
Same author

Effects of β-hydroxy-β-methylbutyrate on skeletal muscle loss in a mouse model of esophageal squamous cell carcinoma.

Annals of translational medicine·2026

Related Experiment Video

Updated: May 21, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

700

Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma.

Taro Mashiko1, Toshihito Ogasawara, Yoshihito Masuoka

  • 1Department of Gastroenterological Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. mt0172@tokai.ac.jp.

The Tokai Journal of Experimental and Clinical Medicine
|March 19, 2025
PubMed
Summary
This summary is machine-generated.

A low C-reactive protein-albumin-lymphocyte (CALLY) index can predict early recurrence in patients with stage I pancreatic ductal carcinoma (PDAC). This inflammation-based prognostic score aids in identifying high-risk individuals for improved management strategies.

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

10.9K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.4K

Related Experiment Videos

Last Updated: May 21, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

700
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

10.9K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.4K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Cancer Prognostics

Background:

  • Pancreatic ductal carcinoma (PDAC) is a highly lethal malignancy.
  • Early recurrence significantly impacts survival in resected early-stage PDAC.
  • Predictive markers for early recurrence are crucial for personalized treatment strategies.

Purpose of the Study:

  • To identify an inflammation-based prognostic score (IBPS) for predicting early recurrence in stage I PDAC.
  • To evaluate the C-reactive protein-albumin-lymphocyte (CALLY) index as a potential predictor.

Main Methods:

  • Retrospective analysis of 109 patients with UICC stage I PDAC who underwent pancreatectomy.
  • Comparison of clinicopathological factors between early recurrence (ER) and non-ER groups.
  • Multivariate analysis to identify independent risk factors for early recurrence.

Main Results:

  • The CALLY index (< 4.4), positive venous invasion, poor tumor differentiation, and incomplete adjuvant chemotherapy were independent risk factors for early recurrence.
  • Patients in the ER group had significantly shorter overall survival.
  • A low pretreatment CALLY index was associated with a higher risk of early recurrence.

Conclusions:

  • The pretreatment CALLY index is a valuable and simple predictor of early recurrence in patients with stage I PDAC.
  • Incorporating the CALLY index into risk stratification may improve postoperative management and patient outcomes.
  • Further validation in larger cohorts is warranted.